Metilfenidato de liberación prolongada 50/50 (medikinet®) dos veces al día, estudio abierto prospectivo

  1. Francisco Montañés Rada 1
  2. Miguel Angel Martínez Granero 2
  3. Margarita Vidal Fermoso 3
  4. Sergio Sanchez Romero 4
  5. Maria Josefa Andrés Prado 5
  1. 1 Jefe de la Unidad de Psiquiatría HUFA (Hospital Universitario Fundación Alcorcón)
  2. 2 Neuropediatra HUFA
  3. 3 Psiquiatra, CSM Arganda.Sergio Sanchez Romero, DUE HUFA
  4. 4 DUE HUFA
  5. 5 Psiquiatra, MIR Preventiva, HUFA
Mostrar afiliaciones +
Revista:
Revista de Psiquiatría Infanto-Juvenil

ISSN: 2660-7271,  1130-9512

Año de publicación: 2012

Volumen: 29

Número: 1

Páginas: 50-58

Tipo: Artículo

DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Revista de Psiquiatría Infanto-Juvenil

Resumen

Se presenta el primer estudio publicado en menores de 18 años (x=13,6; rango:10-16) en el que metilfenidato de liberación prolongada 50/50 de 8 horas de duración (medikinet®) es usado en dos tomas al día.En el contexto de un estudio abierto prospectivo, a 60 derivaciones consecutivas candidatas a tomar estimulan-tes de 8 a 21 horas pero que no podían tomar metilfeni-dato de acción inmediata, se les ofreció tomar dos do-sis de medikinet®: una dosis fija de 30 mg en desayuno (8:00 h) y otra en la tarde (15:00h) que podía ser de10 mg (n=34) ó 20 mg (n=6) con el objetivo de valorar eficacia y tolerancia.No hubo diferencias entre los 40 pacientes incluidos y los 20 no incluidos en el estudio. Los pacientes eran ca-sos moderados-severos (Conners de Profesores superior a 45).A las 8 semanas se alcanzó remisión parcial en el 27,5% (desaparición de al menos el 25% de síntomas ini-ciales) y remisión completa en el 63% de pacientes (sin-drómica en el 12,5%, sintomática en el 25% y funcional en el 22,5%).También se logró reducir la sintomatología de forma estadísticamente significativa (p<0,05) hasta puntos in-feriores a los de población normal, para todas las subes-calas de la escala de Eyberg, Conners de Padres y Profe-sores (excepto para la subescala de conducta del Conners de Profesores).Debido a la aparición de insomnio, 2 pacientes tuvie-ron que reducir dosis medikinet® de la tarde a 10 mg y 3 lo suspendieron por la tarde.

Referencias bibliográficas

  • Scottish Intercollegiate Guidelines Network. Management of attention deficit and Hyperkinetic disorders in children and young people. A National clinical guideline 112. Edimburgo; Oct 2009. [Consultado: 10/06/10]. http://www.sign.ac.uk/ pdf/sign112.pdf
  • National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. (Clinical guideline; no. 72). London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Sep. 59 p. http://guidance.nice.org.uk/CG72
  • Reason R; Working Party of the British Psychological Society. ADHD: a psychological response to an evolving concept. Report of a Working Party of the British Psychological Society. J Learn Disabil. 1999;32(1):85-91.
  • Report of a Working Party of The British Psychological Society. Attention Deficit/ Hyperactivity Disorder (AD/HD): Guidelines and principles for successful multi-agency working. Leicester UK: The British Psychological Society; 2000.
  • Australian Guidelines on Attention Deficit Hyperactivity Disorder (ADHD). Royal Australasian College of Psysicians. June 2009. [Consultado: 10/06/10]. http://www.nhmrc.gov.au/publications/ synopses/adhd_draft.htm
  • Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines, 1re édition, Toronto (ON), CADDRA, 2006. http://www.caddra.ca/ joomla/index.php?Itemid=70 / http://www.caddra. ca/cms4/index.php?option=com_content&view=a rticle&id=26&Itemid=353&lang=en
  • Nutt DJ, Fone K, Asherson P, Bramble D, Hill P, Matthews K, Morris KA, Santosh P, Sonuga-Barke E, Taylor E, Weiss M, Young S. Evidence-based guidelines for management of attention-deficit/ hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology SAGE Publications Ltd. London http://www. bap.org.uk/docsbycategory.php?docCatID=2
  • Evidence Based Clinical Practice Guideline for Outpatient Evaluation and Management of Attention Deficit/Hyperactivity Disorder Guideline 27. Cincinnati Children’s Hospital Medical Center, Cincinnaty 2007. http://www.cincinnatichildrens. org/svc/alpha/h/health-policy/ev-based/adhd.htm
  • E. Taylor, M. Döpfner, J., P. Asherson, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, A. Rothenberger, E. Sonuga-Barke, H.-C. Steinhausen and A. Zuddas. Eur Child Adolesc Psychiatry 2004; [Suppl 1] 13:I/7–I/30.
  • American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105(5): 1158-70.
  • American Academy of Pediatrics. Subcommittee on Attention-Deficit/Hyperactivity, Disorder Committee on Quality, Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001; 108(4): 1033-44.
  • Pliszka S in name of AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention- deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(7):894-921
  • Winters NC, Pumariga A, Work Group on Community Child and Adolescent Psychiatry, Work Group on Quality Issues. Practice parameter on child and adolescent mental health care in community systems of care. J Am Acad Child Adolesc Psychiatry 2007; 46(2): 284-99.
  • Steiner H, Remsing L, Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(1):126-41.
  • Plisszka S, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, McCracken JT, et al and the Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-deficit/ Hyperactivity Disorder. The Texas Childrens Medication Algorithm Project: Revision of the Algorithm for Pharmacotherapy of Attention-Deficit/ Hyperactivity Disorder. J. Am. Acad. Child Adolesc. Psychiatry, 2006; 45(6):642-657.
  • ICSI. Institute for Clinical Systems Improvements. ADHD, Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents, Diagnosis and Management (Guideline) 2007. (Actualizado 04/2010) [Consultado: 10/06/10]: http://www.icsi.org/adhd/adhd_2300. html
  • O’Brian JM, Felt BT, Van Harrison R, Paramjeet KA, Riolo SA, Shehab N. UMHS. University of Michigan Health System. Guidelines for Clinical Care: Attention-Deficit Hyperactivity Disorder. 2005. [Consultado: 10/06/10]. Disponible en: http://cme.med.umich.edu/pdf/guideline/ ADHD05.pdf
  • Sentara Behavioral Health Services Guideline for the Recognition of ADHD in Adults. Sentara Healthcare (SHC). Virginia VA. 2006.
  • Quick Reference Guide. Recommended Screening and Medication Treatment Guidelines for Child and Adolescent Patients with Attention Deficit Hyperactivity Disorder (ADHD). Albuquerque, New Mexico: Lovelace Health Plan and Presbyterian Health Plan: 2007. http://aappolicy.aappublications. org/cgi/reprint/pediatrics;105/5/1158.pdf
  • Du Paul GJ. ADHD identification and assessment: basic Guidelines for educators. Helping Children at Home and School II: Handouts for Families and Educators S8–17. National Association of School Psychologists. Bethesda, MD 2004. www.nasponline. org
  • Montañés-Rada F, Gangoso-Fermoso AB, Martinez- Granero MA. Fármacos para el trastorno por déficit de atención/hiperactividad. Rev Neurol 2009; 48: 469-81.
  • Montañés-Rada F, Gastaminza Pérez X, Catalá MA et al. Consenso del grupo GEITDAH sobre el trastorno por déficit de atención/hiperactividad. Rev Neurol 2010; 51: 633-7.
  • Rosler M, Fischer R, Ammer R, Ose C, Retz W, on behalf of the study group A randomised, placebocontrolled, 24-week, study of low-dose extendedrelease methylphenidate in adults with attentiondeficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009; 259(2):120-9. epub 2009 Jan 22. Erratum in: Eur Arch Psychiatry Clin Neurosci. 2009;259(6):368.
  • Dopfner M, Gerber WD, Banaschewski T, Breuer D, Freisleder FJ, Gerber-von et al. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting. Eur Child Adolesc Psychiatry. 2004; 13(Suppl l):193-l0l
  • Banaschevski T, Coghill D, Santosh P, et al. Longacting medication for the hiperkinetic disorder. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 2006; 15: 476- 9.
  • Conners CK, Erhardt D, Sparrow E . CAARS Conners adult ADHD rating scales. 1999. MHS, New York
  • DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD rating scale-IV. 1998. Guilford, New York
  • Eyberg SM, Robinson EA. Conduct Problem Behavior: Standarization of a behavioural rating scale with adolescents. J Clin Child Psychology. 1983; 12(3) 347-354.
  • Eyberg SM, Ross AW. Assesement of Child Behaviour Problems: The Validation of a New Inventory. J Clin Child Psychology. 1978; (summer): 113-116.
  • Robinson EA, Eyberg SM, Ross AW. The standardization of an inventory of child conduct problems behaviors. J Clin Child Psychology. 1980; (spring) 22-28.
  • Farre-Riba A y Narbona J. Escalas de Conners en la evaluación del trastorno por deficit de atención con hiperactividad: Nuevo estudio factorial en niños españoles. Rev Neurol. 1997; 25 (138): 200- 204.
  • Amador Campos JA. Idiazbal Alecha MA, Aznar Casanova A,Peró Cebollero M. Estructura factorial de la escala de Conners para profesores en muestras comunitaria y clínica. Revista de Psicología General y Aplicada. 2003: 56 (2) 173.184.
  • Fernández de Pinedo R, Gorostiza Garaya E, LAfuente Mesanza P, Ojembarrena Martinez E, Olaskoaga Arrate A. Version Española del ECBI (Eyberg Child Behavior Inventory): medida de validez. Atención Primaria. 1998; 21(2): 65-74.
  • Garcia-Tornel Florensa S, Calzada EJ, Eyberg SM, Mas Alguacil JC, Vilamala Serra C, Baraza Mendoza C, Villena Collado H, Gonzalez García, Calvo Hernández M, Trinxant Domenech A. Inventario de Eyberg Del comportamiento en niños. Normalización de la versión española y su utilidad para el pediatra extrahospitalario. Anal Esp Ped. 1998; 48 (5): 475-482.
  • Biederman J, Mick E and Faraone SV. Age-Dependent Decline of Symptoms of Attention Deficit Hyperactivity Disorder: Impact of Remission Definition and Symptom Type Am J Psychiatry 157:816-818, May 2000.
  • Barkley Russell A Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guilford Press. New York. 2006. Pag 651.
Fuente de los datos: Dialnet